Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Adaptive Randomized Trial of Bevacizumab Versus Bevacizumab Plus TPI 287 in Adults With Recurrent Glioblastoma

NCT01582152 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT01582152
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01582152 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Adaptive Randomized Trial of Bevacizumab Versus Bevacizumab Plus TPI 287 in Adults With Recurrent Glioblastoma
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 1/2
Overall status
Terminated
Start date
July 31, 2012
Completion date
March 31, 2016
Enrollment
12 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

brain neoplasms, central nervous system neoplasms